Page 148 - 南京医科大学学报自然科学版
P. 148
第41卷第9期
·1414 · 南 京 医 科 大 学 学 报 2021年9月
试剂 DOTA.SA.FAPI 的面世,研究者发现当分别使 ment of estrogen receptor⁃positive breast cancer[J].Curr
68
177
用放射性核素镓⁃68( Ga)、镥⁃177( Lu)或镭⁃225 Med Chem,2013,20(5):596⁃604
( Ra)标记该试剂时,有望用于诊断和治疗 [36] 。在 [7] EARLY BREAST CANCER TRIALISTS’COLLABORA⁃
225
TIVE GROUP(EBCT⁃CG),DAVIES C,GODWIN J,et al.
68
对 1 例 31 岁乳腺浸润性导管癌患者行 Ga⁃DOTA.
Relevance of breast cancer hormone receptors and other
SA.FAPI引导下 Lu⁃DOTA.SA.FAPI治疗后,患者头
177
factors to the efficacy of adjuvant tamoxifen:patient⁃level
痛症状明显减轻,实验室指标也逐渐恢复正常,表
meta⁃analysis of randomised trials[J]. Lancet,2011,378
明这种治疗方法可以为乳腺癌患者,尤其是常规治
(9793):771-784
疗无效的患者提供一种新的选择方案 。 [8] KATZENELLENBOGEN J A. The quest for improving the
[37]
7 小 结 management of breast cancer by functional imaging:The
discovery and development of 16α⁃[(18)F]fluoroestradi⁃
随着乳腺癌新型分子靶向药物的发展,PET/CT ol(FES),a PET radiotracer for the estrogen receptor,a
在乳腺癌患者中的地位日益上升。特异性显像剂 historical review[J]. Nucl Med Biol,2021,92:24-37
不仅能识别乳腺癌患者的肿瘤异质性,还有利于患 [9] LIU C,GONG C,LIU S,et al.(18)F⁃FES PET/CT influ⁃
者的分期及进行相应个体化治疗,延长患者生存 ences the staging and management of patients with newly
diagnosed estrogen receptor⁃positive breast cancer:a retro⁃
期。 F⁃FES在显示乳腺癌患者体内ER表达情况及
18
spective comparative study with(18)F⁃FDG PET/CT[J].
预测内分泌治疗效果等方面显示出良好的临床应
Oncologist,2019,24(12):e1277-e1285
用前景,但该显像剂费用较高,且缺乏大量前瞻性
[10] LINDEN H M,KURLAND B F,PETERSON L M,et al.
研究,现阶段广泛应用于临床尚存在一定困难。对 Fluoroestradiol positron emission tomography reveals dif⁃
于临床上仅怀疑乳腺癌发生骨转移的患者可以先 ferences in pharmacodynamics of aromatase inhibitors,
行 F⁃NaF PET/CT 检查,有助于患者节约经费。总 tamoxifen,and fulvestrant in patients with metastatic
18
之,多数显像剂仍处于临床研究阶段,目前仅在小 breast cancer[J]. Clin Cancer Res,2011,17(14):4799-
部分乳腺癌患者中显示出一定优势,后期仍需大量 4805
试验进一步评估这些显像剂在乳腺癌患者诊治方 [11]LIN F I,GONZALEZ E M,KUMMAR S,et al. Utility of
(18)F⁃fluoroestradiol((18)F⁃FES)PET/CT imaging as a
面的应用价值。
pharmacodynamic marker in patients with refractory estro⁃
[参考文献] gen receptor⁃positive solid tumors receiving Z⁃endoxifen
[1] DESANTIS C E,MA J,GAUDET M M,et al. Breast can⁃ therapy[J]. Eur J Nucl Med Mol Imaging,2017,44(3):
cer statistics,2019[J]. CA Cancer J Clin,2019,69(6): 500-508
438-451 [12] WANG Y,AYRES K L,GOLDMAN D A,et al.(18)F⁃Flu⁃
[2] ALLEMANI C,MATSUDA T,DI CARLO V,et al. Global oroestradiol PET/CT measurement of estrogen receptor
surveillance of trends in cancer survival 2000⁃14(CON⁃ suppression during a phase I trial of the novel estrogen re⁃
CORD⁃3):analysis of individual records for 37 513 025 ceptor⁃targeted therapeutic GDC⁃0810:using an imaging
patients diagnosed with one of 18 cancers from 322 popu⁃ biomarker to guide drug dosage in subsequent trials[J].
lation⁃based registries in 71 countries[J]. Lancet,2018, Clin Cancer Res,2017,23(12):3053-3060
391(1125):1023-1075 [13] PAQUETTE M,LAVALLÉE É,PHOENIX S,et al. Im⁃
[3] PAYDARY K,SERAJ S M,ZADEH M Z,et al. The evolv⁃ proved estrogen receptor assessment by PET using the
ing role of FDG ⁃ PET/CT in the diagnosis,staging,and novel radiotracer(18)F ⁃ 4FMFES in estrogen receptor ⁃
treatment of breast cancer[J]. Mol Imaging Biol,2019,21 positive breast cancer patients:an ongoing phase Ⅱ clini⁃
(1):1-10 cal trial[J]. J Nucl Med,2018,59(2):197-203
[4] YEO S K,GUAN J L. Breast cancer:multiple subtypes [14] KUMAR M,SALEM K,TEVAARWERK A J,et al. Re⁃
within a tumor?[J]. Trends Cancer,2017,3(11):753- cent advances in imaging steroid hormone receptors in
760 breast cancer[J]. J Nucl Med,2020,61(2):172-176
[5] BORDONARO S,BERRETTA M,TRALONGO A C,et al. [15] GAO F,PENG C,LI J,et al. Radioiodinated progesterone
The real impact of target therapy in breast cancer pa⁃ derivative for progesterone receptor targeting with en⁃
tients:between hope and reality[J]. Curr Cancer Drug hanced nucleus uptake via phenylboronic acid conjugation
Targets,2018,18(5):480-498 [J]. J Labelled Comp Radiopharm,2019,62(7):301-309
[6] LUMACHI F,BRUNELLO A,MARUZZO M,et al.Treat⁃ [16] SALEM K,KUMAR M,YAN Y,et al. Sensitivity and iso⁃